TNF and myeloid sarcoma: Table 2 summarizes the pharmacogenetic signals statistically significantly associated with response to anti-TNF therapy in RA, PA, SpA, IBD (CD and UC), pediatric IBD (PED-IBD), AS and MS patients, in the years between 2001 and 2015. Additional variant information is contained within Supplementary Materials (Table S2).